Track market-moving stories before they get noisy

Advancing Scalable Reproducible Cell Therapy and Advanced Cell Culture Workflows

New heat-stable and hyperactive proteins across the fibroblast growth factor and interleukin cytokine families expand the R&D Systems™ AI-Engineered Designer Protein portfolio AI-guided protein design supports improved consistency, performance and scalability in complex cell culture workflows Engineered signaling proteins help address key challenges in scaling cell therapy from discovery through manufacturing , /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced the launch of new additions to its R&D Systems™ AI-Engineered Designer Protein portfolio, designed to improve reproducibility and performance across advanced cell culture and cell therapy development workflows.

The R&D Systems AI-Engineered Designer Protein platform enables the design and creation of new protein-based solutions to help researchers overcome current variability and scalability challenges in advanced cell culture by improving the stability and activity of critical reagents.  

By improving protein performance characteristics such as heat stability, activity, and solubility, Bio-Techne helps researchers achieve consistent results and scalable workflows from discovery through therapeutic development. These improvements are critical as cell therapies and organoid systems move toward clinical and commercial scale, where minor variations in cell signaling inputs can significantly impact outcomes.

These additions build on Bio-Techne's strategy to develop a comprehensive portfolio of next-generation signaling technologies, following an earlier expansion of the R&D Systems AI-Engineered Design Protein portfolio. Together, these innovations, including hyperactive cytokines, heat-stable growth factors, and signaling pathway agonists, support stem cell culture, organoid development, and regenerative medicine workflows by enabling more controlled, reproducible systems across the continuum from basic research through process development and scaled-up manufacturing.

Early adopters of R&D Systems AI-Engineered Designer Proteins are already seeing measurable gains in cell expansion and overall workflow performance across demanding applications:

"Many patient-derived Tumor-Infiltrating Lymphocytes (TIL) samples fail during initial outgrowth due to insufficient cell expansion," said Dr Branden Moriarity, Associate Professor in the Division of Pediatric Hematology/Oncology, University of Minnesota. "IL-2 Heat Stable Agonist Protein provides a promising proliferation advantage to TIL samples and also provides clear operational advantages that would reduce the cost of goods for TIL therapies."

This real-world feedback underscores the broader potential of the R&D Systems AI-Engineered Designer Protein platform. With its latest expansion to include additional cytokines and growth factors, the platform is designed to enable more consistent, scalable, and cost-efficient advanced cell culture workflows.

"As cell therapy advances from early research into clinical and commercial manufacturing, achieving consistency, robustness, and scalability across increasingly complex workflows is critical," said Will Geist, President of Bio-Techne's Protein Science Segment. "Our AI-Engineered Designer Proteins are designed to overcome these challenges by delivering enhanced stability, activity, and performance—enabling more reproducible results and supporting seamless scale-up from discovery through production."

The newly launched proteins include:

FGF-4 Heat Stable – Designed to support pluripotent stem cell maintenance, embryonic development research, and differentiation workflows requiring sustained growth factor activity. FGF-7 Heat Stable – Engineered to support epithelial and tissue regeneration workflows, including advanced 3D culture systems and organoid expansion that require sustained stability at elevated temperatures. FGF-8b Heat Stable – Optimized for developmental biology, organoid modeling, and regenerative medicine applications where precise morphogenic signaling is critical. IL-3 Heat Stable – Designed to support hematopoietic stem and progenitor cell expansion and differentiation across early-stage and lineage-committed cell populations requiring sustained cytokine stability in culture. IL-15 Hyperactive – Engineered to drive increased expansion of NK cells and T cells, supporting cell therapy workflows and immunotherapy research, where enhanced signaling strength and persistence are vital. The expansion of the AI-Engineered Designer Protein portfolio reinforces Bio-Techne's leadership in developing high-performance signaling molecules for advanced biological systems. These innovations support organoid culture, stem cell differentiation, and cell therapy manufacturing; areas where reproducible scale-up from discovery to production is increasingly a requirement for success.

For more information about the AI-Engineered Designer Protein portfolio, visit the R&D Systems website.

ABOUT BIO-TECHNE
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company headquartered in Minnesota, celebrating 50 years of empowering scientific and diagnostic communities to reach better answers. The company provides high-quality reagents, analytical instruments, and precision diagnostics. Its portfolio is organized into three customer-focused brands: R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™, reflecting the scientific journey from discovery to translational research to clinical decision-making. Bio-Techne operates in 34 locations worldwide and employs more than 3000 people. In fiscal year 2025, the company generated over $1.2 billion in net sales. Its more than 500,000 products are used globally by academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories.

For more information on Bio-Techne and its brands, please visit www.bio-techne.com or follow the company on social media at LinkedIn and X.

MEDIA CONTACTS:
Corporate Communications
[email protected] 

David Clair, Vice President
Investor Relations
[email protected]

SOURCE Bio-Techne Corporation

MILWAUKEE, July 02, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Bio-Techne (NASDAQ: TECH) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Merck.

Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you.

Bio-Techne shareholders will receive $73 per share in cash, representing a total enterprise value of approximately $11.3 billion. Bio-Techne insiders will receive substantial benefits as part of change of control arrangements.

The transaction agreement unreasonably limits competing transactions for Bio-Techne by imposing a significant penalty if Bio-Techne accepts a competing bid. We are investigating the conduct of the Bio-Techne board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Bio-Techne Corporation (NasdaqGS: TECH) to Merck KGaA. Under the terms of the proposed transaction, shareholders of Bio-Techne will receive $73.00 in cash for each share of Bio-Techne that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or.

, /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Bio-Techne Corporation (NASDAQ: TECH) related to its sale to Merck KGaA. Under the terms of the proposed transaction, Bio-Techne shareholders are expected to receive $73.00 per share in cash. Is it a fair deal?

Click here for more info https://monteverdelaw.com/case/bio-techne-corporation/. It is free and there is no cost or obligation to you.

NOT ALL LAW FIRMS ARE EQUAL. Before you hire a law firm, you should talk to a lawyer and ask:

Do you file class actions and go to Court? When was the last time you recovered money for shareholders? What cases did you recover money in and how much? About Monteverde & Associates PC

Our firm litigates and has recovered money for shareholders…and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court. 

No one is above the law. If you own common stock in the above listed company and have concerns or wish to obtain additional information free of charge, please visit our website or contact Juan Monteverde, Esq. either via e-mail at [email protected] or by telephone at (212) 971-1341.

Contact:
Juan Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4740
New York, NY 10118
United States of America
[email protected]
Tel: (212) 971-1341

Attorney Advertising. (C) 2026 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.

SOURCE Monteverde & Associates PC

Today's Change

(

20.09

%) $

11.82

Current Price

$

70.70

Bio-Techne (TECH +20.09%), a life science reagents, instruments, and bioprocessing tools provider, closed at $70.67, up 20.02%. Merck KGaA’s $73-per-share cash offer drove the move, and investors are watching the deal timetable and any updates on closing conditions. Trading volume reached 51.3M shares, coming in about 1,378% above its three-month average of 3.5M shares.

How the markets moved todayThe S&P 500 (^GSPC 0.01%) finished at 7,357, down 0.01%, while the Nasdaq Composite (^IXIC 0.46%) closed at 25,359, down 0.46%. Among life sciences tools, reagents, instruments, and diagnostics/bioprocessing services peers, Danaher closed at $193.23, up 2.31%, and Repligen closed at $145.23, up 4.93%.

What this means for investorsOne week after it was reported that activist investor Ananym Capital Management had built a stake in Bio-Techne and announced it would be pushing for the company to be sold, a $73-per-share deal from Merck KGaA came in, sending shares soaring. With TECH stock now near $71, it seems the market is optimistic the deal will go through, at a time when $419 billion in healthcare deals have already been completed in 2026 -- the most since 2021.

Profitable and growing sales by 10% annually over the last decade, Bio-Techne will help reload Merck KGaA’s pipeline, adding “complementary strengths across research, bioprocessing, and advanced therapeutics.” The $70 billion acquirer believes it will achieve annualized cost synergies of over $150 million within three years, adding roughly 5% to its bottom line, based on last year’s net income of roughly $3 billion.

Josh Kohn-Lindquist has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Danaher. The Motley Fool recommends Repligen. The Motley Fool has a disclosure policy.

Bio-Techne shareholders will receive $73 per share in cash, representing a 36% premium to the company’s one-month volume-weighted average trading price.

The deal has already been approved by Bio-Techne’s board and the relevant corporate bodies of Merck KGaA and is expected to close in late 2026 or early 2027, pending shareholder and regulatory approvals.

Expanding Life Science Capabilities Across Key Growth AreasMerck KGaA said the acquisition aligns with its medium- and long-term strategy focused on high-growth areas, integrated workflows, and innovation through mergers and acquisitions.

The combination would unite two life sciences companies with complementary portfolios spanning discovery, translational research, development, testing, and commercial manufacturing.

Bio-Techne brings a broad portfolio of recombinant proteins, cytokines, growth factors, antibodies, and immunoassay kits. The company also owns ProteinSimple, which specializes in automated protein detection and analysis instruments.

Additionally, Bio-Techne’s RNAscope and related in situ hybridization technologies are expected to strengthen Merck KGaA’s capabilities in spatial biology and diagnostics.

Cell And Gene Therapy Portfolio Set To Gain ScaleThe acquisition is also expected to enhance Merck KGaA’s position in cell and gene therapy. Bio-Techne currently holds a 19.9% stake in Wilson Wolf Corporation, a manufacturer of cell culture devices, including the G-Rex product line, and expects to acquire the remaining ownership after 2027 under an existing forward contract.

Bio-Techne generated more than $1.2 billion in fiscal 2025 net sales. The company employs more than 3,000 people globally and operates 34 locations and 15 manufacturing facilities across the U.S., Canada, the U.K., Switzerland, and China.

Merck Expects Synergies And Earnings BenefitsMerck KGaA said the transaction will broaden its Process Solutions business by increasing exposure to higher-value reagents, analytics, and advanced research tools while strengthening discovery, development, and manufacturing capabilities.

The acquisition will be financed through a combination of existing cash and new debt, while the company expects to maintain an investment-grade credit rating.

Merck KGaA has cash and cash equivalents of about 2.74 billion euros ($3.11 billion), according to its latest quarterly results. 

Merck KGaA expects the transaction to be immediately accretive to EBITDA pre margin for both its Life Science business and the broader group after closing.

Earnings per share are projected to become accretive by the third year following completion, with annual cost synergies of about 140 million euros ($159.03 million) expected to be fully realized by that time.

TECH Stock Price Activity: Bio-Techne shares were up 19.39% at $70.29 during premarket trading on Thursday, according to Benzinga Pro data.

Photo: Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Bio-Techne Corporation (NASDAQ: TECH) to Merck KGaA for $73.00 per share in cash. Halper Sadeh encourages Bio-Techne shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns whether Bio-Techne and its board of directors violat.

A cyclist drives past a logo of drugs and chemicals group Merck KGaA in Darmstadt, Germany January 28, 2016. REUTERS/Ralph Orlowski/File Photo Purchase Licensing Rights, opens new tab

CompaniesJune 25 (Reuters) - German drugmaker Merck KGaA (MRCG.DE), opens new tab said on Thursday it will acquire U.S. biotech ​firm Bio-Techne Corp (TECH.O), opens new tab for $11.3 billion, expanding its presence ‌in the life sciences market.

Shares of Bio-Techne rose 22% in premarket trading following Merck's offer of $73 per share, which implies a 24% ​premium to Bio-Techne's close on Wednesday.

Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.

With this deal, Merck ​will gain access to Bio-Techne's expertise and supplies ⁠of research reagents, proteins, antibodies, analytical instruments and other ​tools that are used by scientists and drug developers.

The deal ​follows a series of large healthcare transactions this year, including Danaher's (DHR.N), opens new tab $9.9 billion acquisition of patient-monitoring company Masimo in February, as medical technology and life ​sciences firms seek to broaden their product offerings and ​gain market share across multiple segments.

The Bio-Techne acquisition is Merck's largest life ‌sciences ⁠deal since its $17 billion takeover of Sigma-Aldrich in 2014, which bolstered the German group's laboratory supplies and research tools business and accelerated its diversification beyond pharmaceuticals.

The German firm said ​it would fund ​the Bio-Techne ⁠acquisition through a combination of cash and debt. The company has cash and cash equivalents ​of about 2.74 billion euros, according to its ​latest ⁠quarterly results.

The deal is expected to close by late 2026 or early 2027. Merck expects cost savings of about 140 ⁠million ​euros to be fully realized by ​the third year after the deal is closed.

Reporting by Danny Callaghan, Christy Santhosh ​and Padmanabhan Ananthan; Editing by Linda Pasquini and Shinjini Ganguli

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Bio-Techne stock jumps, with Germany's Merck KGaA buying the company at a 24% premium.

The Lanier Law Firm attorney Mark Lanier discusses Roblox's new safety measures, online child protection and Florida's lawsuit against TikTok on ‘Varney & Co.' #foxbusiness #varneyandco 00:00 — Mark Lanier Says Roblox Safeguards Don't Go Far Enough 01:00 — Parents, Phones, and the Growing Child Safety Challenge 01:42 — Florida Targets TikTok Over Child Safety Concerns 03:06 — States Escalate Legal Pressure on OpenAI and Big Tech 04:00 — AI Safety, Minors, and the Future of Tech Regulation

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Biogen Inc. (BIIB) and Techne (TECH). But which of these two stocks is more attractive to value investors?

Posted by Defense World Staff on Apr 17th, 2026

Shares of Bio-Techne Corp (NASDAQ:TECH – Get Free Report) have been assigned an average rating of “Moderate Buy” from the fourteen ratings firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation, nine have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $72.7692.

Several research firms have issued reports on TECH. Wells Fargo & Company boosted their price objective on Bio-Techne from $70.00 to $76.00 and gave the stock an “overweight” rating in a report on Friday, February 6th. Zacks Research upgraded Bio-Techne from a “strong sell” rating to a “hold” rating in a report on Monday, February 9th. Citigroup restated a “buy” rating and set a $80.00 price objective (up from $70.00) on shares of Bio-Techne in a report on Wednesday, February 4th. Weiss Ratings downgraded Bio-Techne from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, March 27th. Finally, TD Cowen restated a “buy” rating on shares of Bio-Techne in a report on Tuesday, March 17th.

Read Our Latest Report on Bio-Techne

Bio-Techne Price Performance Shares of NASDAQ TECH opened at $57.36 on Tuesday. Bio-Techne has a twelve month low of $46.01 and a twelve month high of $72.16. The company has a current ratio of 4.54, a quick ratio of 3.08 and a debt-to-equity ratio of 0.13. The company has a market capitalization of $8.97 billion, a price-to-earnings ratio of 112.47, a PEG ratio of 3.84 and a beta of 1.49. The firm has a 50-day moving average of $55.83 and a two-hundred day moving average of $59.96.

Bio-Techne (NASDAQ:TECH – Get Free Report) last issued its quarterly earnings results on Wednesday, February 4th. The biotechnology company reported $0.46 earnings per share for the quarter, beating analysts’ consensus estimates of $0.43 by $0.03. The company had revenue of $295.88 million during the quarter, compared to the consensus estimate of $290.20 million. Bio-Techne had a net margin of 6.67% and a return on equity of 13.94%. Bio-Techne’s revenue was down .4% on a year-over-year basis. During the same period in the prior year, the company earned $0.42 EPS. As a group, analysts expect that Bio-Techne will post 1.67 earnings per share for the current fiscal year.

Bio-Techne Announces Dividend The business also recently disclosed a quarterly dividend, which was paid on Friday, February 27th. Shareholders of record on Monday, February 16th were issued a dividend of $0.08 per share. This represents a $0.32 annualized dividend and a yield of 0.6%. The ex-dividend date was Friday, February 13th. Bio-Techne’s payout ratio is presently 62.75%.

Institutional Trading of Bio-Techne Institutional investors and hedge funds have recently bought and sold shares of the stock. Diversified Trust Co increased its holdings in shares of Bio-Techne by 25.2% in the 1st quarter. Diversified Trust Co now owns 15,916 shares of the biotechnology company’s stock valued at $832,000 after purchasing an additional 3,206 shares during the period. MidFirst Bank acquired a new position in shares of Bio-Techne in the 4th quarter valued at about $223,000. Alberta Investment Management Corp acquired a new position in shares of Bio-Techne in the 4th quarter valued at about $1,300,000. Wellington Management Group LLP increased its holdings in shares of Bio-Techne by 12.1% in the 4th quarter. Wellington Management Group LLP now owns 5,734,049 shares of the biotechnology company’s stock valued at $337,219,000 after purchasing an additional 618,916 shares during the period. Finally, Alpine Peaks Capital LP increased its holdings in shares of Bio-Techne by 43.1% in the 4th quarter. Alpine Peaks Capital LP now owns 51,500 shares of the biotechnology company’s stock valued at $3,029,000 after purchasing an additional 15,500 shares during the period. Institutional investors and hedge funds own 98.95% of the company’s stock.

Bio-Techne Company Profile (Get Free Report)

Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.

Further Reading Five stocks we like better than Bio-Techne

Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEContrasting Bank of the James Financial Group (NASDAQ:BOTJ) and Customers Bancorp (NYSE:CUBI)

NEXT HEADLINE »KeyCorp Analysts Increase Earnings Estimates for Tetra Tech

Key Takeaways TECH is set to report Q3 fiscal 2026 results on May 6, with revenues seen rising 1.1% year over year. Bio-Techne's Protein Sciences may benefit from pharma strength and stabilizing biotech and academic demand. TECH's Diagnostics and Spatial Biology could see mixed trends, with growth in RNAscope and COMET bookings. Bio-Techne Corporation (TECH - Free Report) is set to release third-quarter fiscal 2026 results on May 6, before the opening bell.

The life science and diagnostic product maker posted adjusted earnings per share (EPS) of 46 cents in the last reported quarter, which beat the Zacks Consensus Estimate by 7%. The company’s earnings beat estimates in three of the trailing four quarters and matched once, the average surprise being 5.70%.

Q3 Estimates for TECHThe Zacks Consensus Estimate for revenues is pegged at $319.7 million, indicating an increase of 1.1% from the year-ago reported figure.

The consensus estimate for EPS is pinned at 55 cents, indicating a decrease of 1.8% from the year-ago reported figure.

Estimate Revision Trend Ahead of TECH’s Q3 EarningsEstimates for earnings have remained constant at 55 cents per share in the past 30 days.

Let’s briefly review the company’s performance leading up to the announcement.

TECH: Factors at Play Before Q3 ResultsDuring the previous earnings call, management noted that funding uncertainty has affected customer behavior in emerging biotech and U.S. academia end markets. However, recent strength in biotech funding activity, along with favorable U.S. fiscal 2026 appropriation bills, positions both end markets for continued stabilization and gradual improvement.

Protein Sciences 

The company’s core portfolio of research-use-only proteomic agents — featuring more than 6,000 proteins and 400,000 antibody types — might have continued to support global customers in advancing therapeutics to enable precision diagnostics. Revenues might have been positively impacted by the ongoing strength in pharmaceuticals, along with stabilization across U.S. academia and biotech end markets. Aside from the two largest cell therapy customers (who temporarily reduced purchases), GMP reagents are likely to have witnessed strong growth, underscoring the strength of its offering and improving end-market demand. 

In the fiscal third quarter, the protein analytical instrumentation business might have continued to demonstrate strong momentum. Additionally, the Wilson Wolf business is likely to have stood out as a high-growth opportunity in the to-be-reported quarter. In the previous quarter, the company’s fully automated proteomic analytical solution, ProteinSimple, achieved high single-digit growth. We expect this trend to have persisted in the to-be-reported quarter as well. 

Meanwhile, within the Simple Western portfolio, demand for the next-generation high-throughput instrument, Leo, appears to have been strong. In December, the company expanded the launch and completed its first shipments of the Leo System. We expect this development to have contributed to the quarterly performance.

Major developments within the segment include the launch of Simple Plex Ultra-Sensitive Assays on the Ella automated benchtop platform and Cultrex Synthetic Hydrogel — a fully defined synthetic extracellular matrix, to support reproducible and scalable 3D stem cell and organoid research. Additionally, the Ella benchtop immunoassay platform has received CE-IVD marking and is now available for sale in the European Union. 

In the previous quarter, Bio-Techne signed a licensing agreement with Monod Bio, which grants Bio-Techne exclusive commercial rights to a specific subset of Monod’s NovoBody Duo molecules — a new class of AI-designed bispecific binding proteins. These initiatives might have contributed to the company’s fiscal third-quarter top-line performance.

The consensus estimate for the segment’s revenues is pegged at $232.7 million, up 2.2% from the year-ago reported figure.

Bio-Techne Corp Price and EPS SurpriseDiagnostics and Spatial Biology

In the fiscal third quarter, the RNAscope product suite, which is used to detect and visualize RNA and short microRNA sequences at the single-cell level within intact tissue samples, might have experienced growth similar to that in the previous quarter.

The COMET instrument might have recorded year-over-year growth in bookings. The company might have also continued to see momentum for the ESR1 test, which monitors resistance to standard therapies in breast cancer patients. In the previous quarter, the Diagnostics business delivered high single-digit growth, supported by balanced performance across both clinical controls and molecular diagnostic kits. We expect this trend to have persisted in the to-be-reported quarter as well. 

Major developments within the segment include the expansion of its COMET solution portfolio with the addition of the new SPYRE Focus Panels and SPYRE Amplification Kits. In the previous quarter, Bio-Techne also signed an agreement between one of its spatial biology brands, Lunaphore, and the Wyss Center for Bio and Neuroengineering to develop an automated workflow for simultaneous RNA and protein detection in 3D specimens. The company also launched the ProximityScope assay, a novel spatial solution designed for seamless integration with the BOND RX staining platform from Leica Biosystems. These initiatives might have contributed to the company’s fiscal third-quarter top-line performance.

The consensus estimate for Spatial Biology revenues is pegged at $86.9 million, down 2.6% from the year-ago reported figure.

What Our Model Unveils for TECHPer our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates, which is not the case here, as you can see.

Earnings ESP: Bio-Techne has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Zacks Rank: The company currently carries a Zacks Rank #3 (Hold). 

Top MedTech PicksHere are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time:

Agenus (AGEN - Free Report) has an Earnings ESP of +7.69% and a Zacks Rank #1. The company is expected to release first-quarter 2026 results soon. You can see the complete list of today’s Zacks #1 Rank stocks here.

In the trailing four quarters, AGEN delivered an average surprise of 31.42%. The Zacks Consensus Estimate for the company’s first-quarter EPS is expected to increase 289.3% from the year-ago quarter’s figure.

Encompass Health (EHC - Free Report) has an Earnings ESP of +0.17% and a Zacks Rank #2. The company is slated to release first-quarter 2026 results on April 30.   

EHC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 12.09%. The Zacks Consensus Estimate for EHC’s first-quarter EPS is anticipated to rise 10.2% from the year-ago reported figure.

The Ensign Group (ENSG - Free Report) has an Earnings ESP of +1.12% and a Zacks Rank #2. The company is expected to release first-quarter 2026 results soon.

ENSG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 2.93%. The Zacks Consensus Estimate for the company’s first-quarter EPS calls for an increase of 17.8% from the year-ago quarter’s figure.

, /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended March 31, 2026. The quarterly dividend will be payable May 29, 2026, to all common shareholders of record on May 18, 2026. Future cash dividends will be considered by the Board of Directors on a quarterly basis.

Bio–Techne Corporation (NASDAQ: TECH) is a global life sciences company headquartered in Minnesota, celebrating 50 years of empowering scientific and diagnostic communities to reach better answers. The company provides high–quality reagents, analytical instruments, and precision diagnostics. Its portfolio is organized into three customer–focused brands: R&D Systems™, Bio–Techne Spatial™, and Bio–Techne Diagnostics™, reflecting the scientific journey from discovery to translational research to clinical decision–making. Bio–Techne operates in 34 locations worldwide and employs approximately 3,100 people. In fiscal year 2025, the company generated over $1.2 billion in net sales. Its more than 500,000 products are used globally by academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories. For more information on Bio-Techne and its brands, please visit www.bio-techne.com or follow the company on social media at LinkedIn, X, or YouTube. 

Forward Looking Statements:
Our press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such statements involve risks and uncertainties that may affect the actual results of operations. Forward looking statements in this press release include statements regarding potential future repurchase of Bio-Techne common stock. The following important factors, among others, have affected and, in the future, could affect the Company's actual results and future share price: the effect of new branding and marketing initiatives, the integration of new businesses and leadership, the introduction and acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, customer site closures or supply chain issues, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships.

For additional information concerning such factors, see the section titled "Risk Factors" in the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements.

Contact: 

David Clair, Vice President, Investor Relations

[email protected]

612-656-4416

SOURCE Bio-Techne Corporation

CompaniesMay 6 (Reuters) - Biotech firm Bio-Techne (TECH.O), opens new tab on Wednesday missed Wall Street estimates for third-quarter revenue, as cuts to U.S. ​academic funding weighed on demand for its drug-development ‌products.

Here are some details:

Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.

The Minneapolis, Minnesota-based company, develops products used in medical research, drug development and diagnostics.

Bio-Techne's quarterly sales ​came in at $311.4 million, below analysts' expectations ​of $317.1 million, according to data compiled by LSEG.

Uncertainty ⁠due to cuts to U.S. academic funding ​as well as concerns related to President Donald Trump's ​tariffs have been weighing on the company's clients.

CEO Kim Kelderman said demand has yet to recover broadly, adding that while ​biotech funding remains healthy, it "has not yet ​translated into broad-based demand across our portfolio."

But early indicators point to a ‌more ⁠constructive outlook as funding activity and customer purchasing begin to realign, Kelderman added.

U.S. academic markets stabilized with low-single-digit growth in the quarter, the company ​said.

Sales at the ​company's largest ⁠protein sciences unit, which develops and makes biological compounds for research and diagnostics, fell ​1% to $226.2 million, below analysts' estimates of $230.63 ​million.

Revenue ⁠from its diagnostics and genomics unit, which makes tools and compounds for therapeutics and vaccines, dropped 4% to $85.6 million, missing expectations of $86.58 ⁠million.

The ​company earned adjusted profit per ​share of 53 cents for the quarter, missing estimates of 54 cents.

Reporting ​by Siddhi Mahatole in Bengaluru; Editing by Leroy Leo

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Key Takeaways Bio-Techne reported Q3 EPS of 53 cents, missing estimates and falling 5.4% year over year. TECH posted $311.4M in sales, down 1.5%, though still beating consensus estimates. Bio-Techne's operating margin rose 1200 bps to 24.2%, driven by lower expenses. Bio-Techne Corporation (TECH - Free Report) reported third-quarter fiscal 2026 adjusted earnings per share (EPS) of 53 cents, which missed the Zacks Consensus Estimate by 2.8%. The bottom line was down 5.4% on a year-over-year basis. 

The quarter's adjustments eliminated the impact of certain one-time items, including amortization of Wilson Wolf intangible assets, and restructuring and restructuring-related costs, among others.

GAAP EPS was 32 cents compared with 14 cents in the prior-year quarter.

TECH's Revenues in DetailBio-Techne registered net sales of $311.4 million, reflecting a decline of 1.5% year over year on a reported basis. The figure was down 2% on an organic basis. The top line missed the Zacks Consensus Estimate by 2.4%.

Following the announcement, shares of Bio-Techne declined 1.2% in pre-market trading yesterday, reflecting investor reaction to the company’s quarterly sales and earnings decline. 

Segmental Analysis of TECH’s Q3 RevenuesThe company reports under two business segments — Protein Sciences, and Diagnostics and Spatial Biology (formerly Diagnostics and Genomics).

Within Protein Sciences, Bio-Techne recorded revenues of $226.2 million, down 1% year over year (down 4% organically). In fiscal 2024, a business within this segment met the criteria as held-for-sale, excluded from its operating results.

Within Diagnostics and Spatial Biology, sales decreased 4% year over year to $85.6 million (up 3% organically) in the fiscal third quarter. Within this, the Exosome Diagnostics business met the held-for-sale criteria, excluded from its operating results.

TECH’s Q3 MarginsBio-Techne’s gross profit fell 2.9% to $208.3 million. The gross margin contracted 97 basis points (bps) to 66.9% on a 1.5% rise in the cost of sales.

Selling, general and administrative expenses declined 27.7% to $109.3 million. Research and development expenses totaled $23.4 million, down 4.6% year over year. 

The company generated an operating profit of $75.5 million in the fiscal third quarter compared with the year-ago quarter’s figure of $38.7 million. The operating margin expanded 1200 bps to 24.2% during the quarter. 

Bio-Techne Corp Price, Consensus and EPS SurpriseBio-Techne’s Capital StructureBio-Techne exited the fiscal third quarter of 2026 with cash and equivalents of $209.8 million compared with $172.9 million at the end of the fiscal second quarter. Long-term debt obligations totaled $200 million compared with $260 million in the previous quarter. 

Cumulative net cash provided by operating activities was $196.7 million compared with $189.3 million a year ago.

Our Take on Bio-Techne’s ResultsBio-Techne ended the reported quarter with lower-than-expected results, wherein both earnings and revenues missed estimates. Also, quarterly revenue decline and gross margin contraction look discouraging. 

Large pharma delivered the sixth consecutive quarter of double-digit growth, which was offset by a continued lag in spending by emerging biotech. U.S. academic markets stabilized with low-single digit growth. Growth vectors performed well, with mid-single digit growth in Proteomic Analysis instruments, mid-teens growth in Spatial Biology, and nearly 50% growth in GMP proteins excluding fast track customers. 

The expansion of operating margin bodes well. 

TECH's Zacks Rank and Key PicksBio-Techne currently has a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Intuitive Surgical (ISRG - Free Report) and Phibro Animal Health (PAHC - Free Report) .

Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a fourth-quarter 2025 adjusted EPS of $1.28, which surpassed the Zacks Consensus Estimate by 20.8%. Revenues of $826.4 million beat the Zacks Consensus Estimate by 4.9%. You can see the complete list of today’s Zacks #1 Rank stocks here.

GMED has an earnings yield of 4.7% compared to the industry’s negative yield of 1.4%. The company’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 18.79%.

Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, posted a first-quarter 2026 adjusted EPS of $2.50, which exceeded the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion topped the Zacks Consensus Estimate by 6.2%.

ISRG has an earnings yield of 2.1% in contrast to the industry’s negative yield of 0.9%. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 16.82%.

Phibro Animal Health, carrying a Zacks Rank #2 at present, posted a second-quarter fiscal 2026 adjusted EPS of 87 cents, which outpaced the Zacks Consensus Estimate by 27.01%. Revenues of $373.9 million outperformed the Zacks Consensus Estimate by 4.72%.

PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.1% growth. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 20.15%.

ANTWERP, Belgium, 7 May 2026 – CMB.TECH NV (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) (“CMBT”, “CMB.TECH” or “the Company”) will release its first quarter 2026 earnings prior to market opening on Tuesday 19 May 2026 and will host a conference call at 8 a.m. EST / 2 p.m. CET to discuss the results for the quarter.

The call will be a webcast with an accompanying slideshow. You can find the details of this conference call below and on the “Investor Relations” page of the website. The presentation, recording & transcript will also be available on this page.

Webcast Information Event Type: Video conference call with slide presentationEvent Date:19 May 2026Event Time:8 a.m. EST / 2 p.m. CETEvent Title: “Q1 2026 Earnings Conference Call”Event Site/URL:  https://events.teams.microsoft.com/event/9600de65-6747-468b-bb10-eb435b6a1780@d0b2b045-83aa-4027-8cf2-ea360b91d5e4 To attend this conference call, please register via the following link.

Telephone participants who are unable to pre-register may dial in to the respective number of their location (to be found here). The Phone conference ID is the following: 266 848 625#

Announcement Q1 2026 results – 19 May 2026

About CMB.TECH

CMB.TECH (all capitals) is one of the largest listed, diversified and future-proof maritime groups in the world with a combined fleet of about 250 vessels: dry bulk vessels, crude oil tankers, chemical tankers, container vessels and offshore energy vessels. CMB.TECH also offers hydrogen and ammonia fuel to customers, through own production or third-party producers.

CMB.TECH is headquartered in Antwerp, Belgium, and has offices across Europe, Asia and Africa.

CMB.TECH is listed on Euronext Brussels and the NYSE under the ticker symbol “CMBT” and on Euronext Oslo Børs under the ticker symbol “CMBTO”.

More information can be found at https://cmb.tech

Forward-Looking Statements

Matters discussed in this press release may constitute forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides safe harbour protections for forward-looking statements in order to encourage companies to provide prospective information about their business. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts. The Company desires to take advantage of the safe harbour provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbour legislation. The words "believe", "anticipate", "intends", "estimate", "forecast", "project", "plan", "potential", "may", "should", "expect", "pending" and similar expressions identify forward-looking statements.

The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, our management's examination of historical operating trends, data contained in our records and other data available from third parties. Although we believe that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond our control, we cannot assure you that we will achieve or accomplish these expectations, beliefs or projections.

In addition to these important factors, other important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include the failure of counterparties to fully perform their contracts with us, the strength of world economies and currencies, general market conditions, including fluctuations in charter rates and vessel values, changes in demand for tanker vessel capacity, changes in our operating expenses, including bunker prices, dry-docking and insurance costs, the market for our vessels, availability of financing and refinancing, charter counterparty performance, ability to obtain financing and comply with covenants in such financing arrangements, changes in governmental rules and regulations or actions taken by regulatory authorities, potential liability from pending or future litigation, general domestic and international political conditions, potential disruption of shipping routes due to accidents or political events, vessels breakdowns and instances of off-hires and other factors. Please see our filings with the United States Securities and Exchange Commission for a more complete discussion of these and other risks and uncertainties.

This information is published in accordance with the requirements of the Continuing Obligations on Euronext Oslo Børs

Contact

CMB.TECH
Katrien Hennin
Head of Marketing and Communications
+32 499 39 34 70
[email protected]

Joris Daman
Head of Investor Relations
Tel: +32 498 61 71 11
[email protected]

CMBT_Q1_Earnings_Notice_ENG

CMB.TECH ANNOUNCES Q1 2026 RESULTS
FIRING ON ALL CYLINDERS

ANTWERP, Belgium, 19 May 2026 – CMB.TECH NV (“CMBT”, “CMB.TECH” or “the company”) (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) reported its unaudited financial results today for the first quarter ended 31 March 2026.

HIGHLIGHTS

Financial highlights: Profit for the period of USD 368.8 million in Q1 2026. EBITDA for the same period was USD 558.3 million.CMB.TECH’s contract backlog increased to USD 3.26 billion with the addition of 1 x 5-year Suezmax time charter and extension of 2 x Suezmax time charters by one year to a 10-year time charter each (with a profit split).Intention to distribute an amount of USD 0.64 per share. Fleet highlights:

Delivery of 7 newbuilding vessels (Q1 + Q2 to date): Newcastlemaxes: Mineral LatvijaVLCCs: Eburones, MenapiiSuezmaxes: Cap Grace, Cap JosephChemical tanker: Bochem CallaoCSOV: Windcat Haarlem Previously announced sale of 8 VLCCs: Daishan (2007, 306,005 dwt), Hirado (2011, 302,550 dwt), Ilma (2012, 314,000 dwt), Ingrid (2012, 314,000 dwt), Hojo (2013, 302,965 dwt), Dia (2015, 299,999 dwt), Antigone (2015, 299,421 dwt), and Aegean (2016, 299,999 dwt). Previously announced sale of Capesize vessels Golden Magnum (2009, 179,790 dwt), and Belgravia (2009, 169,390 dwt). Sale of Suezmax Sienna (2007 - 150,205 dwt). The sale will generate a gain of USD 29.2 million and is expected to be recognised upon delivery in the second quarter of 2026. For the first quarter of 2026, the company realised a net gain of USD 368.8 million or USD 1.27 per share (first quarter 2025: a net gain of 40.4 USD million or USD 0.23 per share). EBITDA (a non-IFRS measure) for the same period was USD 558.3 million (first quarter 2025: USD 158.4 million).

“CMB.TECH is firing on all cylinders. We are reaping the benefits of a red-hot tanker market through a mix of sales of older vessels at stellar prices, a historically high spot market and the addition of lucrative long-term charters. At the same time, the dry bulk market is powering on in all segments, but specifically Capesizes and Newcastlemaxes. Our spot results have been strong during Q1 and will be even stronger in Q2. With HFO prices up by 50 %, we manage to extract more profit from the going market rates thanks to our very modern and super eco fleet. Last but not least, our offshore energy division Windcat has been able to fix two of its CSOVs at excellent rates, testimony to the high quality of our vessels.

We are harvesting the fruits of our hard work over the past two years: well-timed newbuilding orders, well-timed acquisitions and a market which is going our way.

We don’t know how long this Goldilocks moment will continue amidst many uncertainties surrounding global trade and a growing orderbook. But we will use the current momentum to continue to strengthen our balance sheet, pay dividends and convert some of the current market strength into longer term charters.” - Alexander Saverys, CEO CMB.TECH.

Key figures

         The most important key figures (unaudited) are:               (in thousands of USD)   First Quarter 2026 First Quarter 2025          Revenue          519,630         235,044  Other operating income          20,331         7,134          Raw materials and consumables          (1,409)         (2,809)  Voyage expenses and commissions          (104,819)         (42,404)  Vessel operating expenses          (127,487)         (61,829)  Charter hire expenses          (218)         (313)  General and administrative expenses          (27,787)         (22,847)  Net gain (loss) on disposal of tangible assets          267,354         46,451  Depreciation and amortisation          (106,571)         (55,671)  Impairment reversals          589         —          Net finance expenses          (81,697)         (64,215)  Share of profit (loss) of equity accounted investees          12,096         (51)  Result before taxation          370,012         38,490          Income tax benefit (expense)          (1,178)         1,883  Profit (loss) for the period          368,834         40,373          Attributable to:        Owners of the Company          368,834         43,998   Non-controlling interest          —         (3,625)                 Earnings per share:             (in USD per share) First Quarter 2026 First Quarter 2025         Weighted average number of shares (basic) *         290,169,769         194,216,835          Basic earnings per share         1.27         0.23                        The number of shares issued on 31 March 2026 is 315,977,647. However, the number of shares excluding the owned shares held by CMB.TECH at 31 March 2026 is 290,169,769.          EBITDA reconciliation (unaudited):               (in thousands of USD)  First Quarter 2026 First Quarter 2025          Profit (loss) for the period          368,834         40,373          + Net finance expenses          81,697         64,215          + Depreciation and amortisation          106,571         55,671          + Income tax expense (benefit)          1,178         (1,883)          EBITDA (unaudited)          558,281         158,376                          EBITDA per share:               (in USD per share)  First Quarter 2026 First Quarter 2025          Weighted average number of shares (basic)          290,169,769         194,216,835          EBITDA          1.92         0.82                          All figures, except for EBITDA, have been prepared under IFRS as adopted by the EU (International Financial Reporting Standards) and have not been audited nor reviewed by the statutory auditor.

Intention of distribution

The Supervisory Board intends to approve a total distribution of USD 0.64 per share (the "Distribution"), which is proposed to be a combination of (i) an interim dividend of USD 0.20 per share (subject to 30% withholding tax, to the extent no exemption or reduction applies) and (ii) a first payment of USD 0.44 per share out of the share premium reserve (which is exempt from withholding tax).

The approval of the Distribution by the Supervisory Board is subject to, and conditional upon:

(i) the approval by the General Shareholders' Meeting of CMB.TECH, scheduled for 21 May 2026, of the agenda item relating to the distribution out of the share premium reserve; and

(ii) the completion of the corporate procedures prescribed by the Belgian Companies and Associations Code (Wetboek van vennootschappen en verenigingen / Code des sociétés et des associations) with respect to the interim dividend.

CMB.TECH will provide further information on the payment date, record date and other practical modalities of the Distribution once the Distribution is effectively approved (currently scheduled for end of May 2026), in accordance with applicable regulations.

TCE

The average daily time charter equivalent rates (TCE, a non IFRS-measure) can be summarised as follows:

 Q1 2026Q1 2025Quarter-to-Date Q2 2026USD/dayUSD/dayUSD/dayFixed %DRY BULK VESSELSNewcastlemax average spot rate(1)28,12018,39344,10580%Newcastlemax average time charter rate24,114   Capesize average spot rate(1)26,104 37,70173%Panamax/Kamsarmax average spot rate(1)14,578 19,40274%Panamax/Kamsarmax average time charter rate13,456   TANKERSVLCC average spot rate (2)70,20435,101182,73181%VLCC average time charter rate(3)55,14446,135  Suezmax average spot rate(1) (3)91,84941,391122,14783%Suezmax average time charter rate33,90531,328  CONTAINER VESSELSAverage time charter rate29,37829,378  CHEMICAL TANKERSAverage spot rate(1) (2)21,45820,52121,06333%Average time charter rate19,30619,306   OFFSHORE ENERGYCSOV Average time charter rate64,837 62,301100%CTV Average time charter rate2,6092,3763,41491% 1) Reporting load-to-discharge for actual TCEs, in line with IFRS 15, net of commission
(2) CMB.TECH owned ships in TI Pool or Stolt Pool (excluding technical off hire days)
(3) Including profit share where applicable

CMB.TECH FLEET DEVELOPMENTS

Commercial contracts

CMB.TECH’s contract backlog increased by USD 109 million to USD 3.26 billion:

1 x 5-year Suezmax time charter: Cedar (2011, 165,000 dwt)Extension 2 x Suezmax time charters by one year to a 10-year time charter each: Cap Grace (2026, 156,000 dwt), Cap Joseph (2026, 156,000 dwt) (with profit split) Sales

Following vessels were delivered to new owners in Q1 2026 - generating a total capital gain of approximately USD 267.4 million:

Capesize vessels Golden Magnum (2009, 179,790 dwt), and Belgravia (2009, 169,390 dwt) - capital gain of approximately USD 8.1 million in Q1 2026, based on the net sales price and book valuesSix VLCCs: Daishan (2007, 306,005 dwt), Hirado (2011, 302,550 dwt), Hojo (2013, 302,965 dwt), Dia (2015, 299,999 dwt), Antigone (2015, 299,421 dwt), and Aegean (2016, 299,999 dwt) - capital gain of approximately USD 259.3 million in Q1 2026, based on the net sales price and book values. Following vessels will be delivered to new owners in Q2 2026:

Two VLCCs: Ilma (2012, 314,000 dwt) and Ingrid (2012, 314,000 dwt) - capital gain of approximately USD 98.2 million in Q2 2026, based on the net sales price and book values.One Suezmax Sienna (2007, 150,205 dwt). The sale will generate a gain of USD 29.2 million and is expected to be recognised upon delivery in the second quarter of 2026. Newbuilding deliveries

Delivery dateType of vesselName12 January 2026VLCCEburones (2026, 319,000 dwt)13 January 2026Chemical tankerBochem Callao (2026, 25,000 dwt)23 March 2026VLCCMenapii (2026, 319,000)8 April 2026SuezmaxCap Grace (2026, 156,000 dwt)27 April 2026SuezmaxCap Joseph (2026, 156,000 dwt)4 May 2026CSOVWindcat Haarlem (2026)11 May 2026NewcastlemaxMineral Latvija (2026, 210,000 dwt) MARKET & OUTLOOK

Bocimar – Dry-Bulk Market1

The dry bulk markets entered 2026 with strong momentum, with the Baltic Dry Index averaging materially higher year-on-year in Q1 and spot earnings across major vessel classes trending well above seasonal norms. Capesize C5TC (BCI-182) time charter equivalent (TCE) earnings averaged USD 26,405 per day during Q1 2026, compared to a 10-year historical average of USD 16,350 per day2. Average sector earnings in the first quarter were supported by robust major bulk volumes, firm minor bulk activity, and generally tighter effective fleet supply. Continuing on a strong Q1, the Capesize C5TC (BCI-182) average for April stands at 34,920 USD/day, the strongest since April 2001 and 15,263 USD/day higher compared to April 2025 (BCI-182 recalculated basis) – and increased further up to 48,433 USD/day on 13 May.

Iron ore trade demonstrated notable resilience in Q1 2026, with seaborne volumes underpinned by stable Chinese import demand, which increased by 11.0% quarter-to-date year-on-year. Although Chinese steel production showed regional variability, consistent blast furnace utilisation rates and firm export activity continued to support demand for high-grade iron ore. Inventory levels, while elevated in absolute terms, remained within a manageable range at approximately 35 days of consumption, compared to a 2010–2025 average of around 30 days. From a dry bulk shipping perspective, Capesize demand continues to be more closely linked to production and export volumes from major mining companies rather than fluctuations in steel production. In this context, Q1 2026 production guidance from leading miners reaffirmed a constructive outlook, with Rio Tinto guiding 343–366 MMT for 2026, Vale 335–345 MMT for 2026, and Fortescue 195–205 MMT for the 2025/2026 period. In addition, the Simandou project has begun to ramp up meaningfully in early 2026, with the port stockpile increasing to above 2 MMT by the end of Q1 and seaborne shipments rising from approximately 0.6 MMT in Q1 to around 1.2 MMT in April alone, marking a clear step-change in export volumes. Furthermore, vessel activity at Morebaya port is increasing, with a growing number of Capesize vessels observed waiting and loading Simandou cargoes on a month-over-month basis.

In addition to long-haul iron ore flows, Q1 2026 Capesize demand continued to benefit from the sustained ramp-up in bauxite exports from Guinea. Seaborne bauxite volumes maintained strong momentum, increasing by 9.6 MMT year-on-year, or 14.8%. Further support for ton-mile demand has come from logistical disruptions in the Middle East. The closure of the Strait of Hormuz has effectively re-routed approximately 9% of global aluminium production, creating additional demand for both bauxite and alumina shipments over longer distances. Market speculation has re-emerged regarding the potential introduction of export restrictions in Guinea at a level of 150 MMT per annum. At this stage, such measures remain unconfirmed. Available data continues to point to robust growth, with April bauxite exports reaching 23.1 MMT, representing a year-on-year increase of 12.4%. Pending any formal policy changes, the prevailing trend remains one of expanding long-haul cargo volumes, providing continued support to Capesize utilisation and a firmer freight market.

On the demand side, coal has emerged as a key upside driver in 2026. Market dynamics were significantly shaped by disruptions in global gas supply during the quarter. The temporary loss of approximately 80 mtpa of Qatari LNG capacity has been effectively offset by increased seaborne coal demand, with April coal exports rising by around 7.5% year-on-year (7.6 MMT). Elevated natural gas prices have further incentivised gas-to-coal switching, particularly across Europe and parts of Northeast Asia (Japan, South Korea, and Taiwan). This has supported increased thermal coal imports into the EU, India, and select Asian markets. Even in the event of a reopening of the Strait of Hormuz, structural constraints are expected to persist. Trains S4 and S6 at the Ras Laffan complex are projected to remain offline for the next 3–5 years, removing 12.8 mtpa of LNG supply and implying an incremental coal demand boost of approximately 39.7 MMT, or +3.0%. Metallurgical (coking) coal volumes, meanwhile, have remained relatively stable, underpinned by restocking activity and resilient Australian supply. Looking ahead, emerging El Niño conditions may provide an additional tailwind. Historically, reduced hydroelectric output in China during such periods has driven spikes in coal imports, most notably a 52% increase in 2023 (+130MMT).

Grain and agribulk shipments followed typical seasonal patterns, with strong South American soybean flows offset by softer Middle East–bound volumes, where rerouting and execution risk linked to the Strait of Hormuz limited trade visibility. Looking ahead, evolving El Niño conditions may further reshape trade flows. Potential drought impacts in Australia could weigh on grain export volumes, while improved weather conditions in Latin America are expected to support stronger harvests and higher export availability. This shift in regional supply dynamics would likely increase average voyage distances, providing incremental tonne-mile demand for the Kamsarmax/Panamax dry bulk fleet. In addition, El Niño-related constraints on Panama Canal draught levels tend to disproportionately impact the Kamsarmax segment, meaning that Panama Canal transits may become constrained during peak US agribulk export season in Q4 2026, driving additional re-routing and a corresponding increase in tonne-mile demand.

On the supply side, effective fleet growth remained constrained despite a gradually expanding newbuilding orderbook (Capesize OB/F 14.57%; Panamax OB/F 14.26%). A combination of slower sailing speeds (down 2.9% since the start of Operation Epic Fury), elevated bunker prices, periodic congestion, and temporary vessel displacement linked to geopolitical disruptions continued to limit effective capacity. Simultaneously, the fleet is ageing rapidly. Vessels delivered during the 2000–2008 ordering cycle are now approaching 20 years of age. By 2030, an estimated 39% of the fleet will be 20 years or older, an evolution that is already having a tangible impact on fleet efficiency. Capesize vessels transitioning from 17 to 18 years of age typically experience an average utilisation decline of approximately 13% in that year alone, with utilisation falling by a further 31% over the subsequent five years. Next to constrained yard capacity, also elevated newbuilding prices further constrain supply growth. At current time charter rate levels, returns do not meet an 8% unlevered hurdle, acting as a natural brake on new ordering activity. Absent a sustained increase in freight rates, the conditions required to trigger a meaningful fleet renewal cycle are unlikely to materialise.

Bocimar has 38 (+8NB) Newcastlemaxes on the water (average age 3.2y), 37 Capesize vessels on the water (average age 11.2), and 30 Kamsarmax/Panamax vessels on the water (average age 6.9y).

Bocimar performance highlights (in USD):

 TCE Q1 2026QTD Q2 2026Newcastlemax28,12044,105 (80% fixed)Capesize26,10437,701 (73% fixed)Kamsarmax/Panamax14,57819,402 (74% fixed) Euronav – Tanker Markets3

Crude tanker markets experienced exceptional volatility during Q1 2026, primarily driven by escalating geopolitical tensions in the Middle East and the disruption of shipping flows through the Strait of Hormuz. Transit volumes through the Strait declined materially, temporarily removing a meaningful portion of the VLCC (115 vessels) and Suezmax (24 vessels) fleets from effective supply. The resulting scramble for available tonnage led to sharp spikes in spot freight rates across key benchmark routes. However, it is important to note that parts of this rate surge were largely indicative, as actual fixture activity in the Middle East remained almost non-existent during the period, rendering some benchmarks effectively paper based. Against this backdrop, VLCC time charter equivalent (TCE) earnings averaged USD 156,601 per day in Q1 2026, compared to a 10-year historical average of USD 46,504 per day. Suezmax earnings followed a similar trajectory, with Q1 2026 TCE averaging USD 152,067 per day versus a 10-year average of USD 44,565 per day.

Over time, the disruption to crude oil flows has driven a gradual rebalancing of global trade patterns. Increased reliance on Atlantic Basin supply, most notably higher U.S. crude exports to Europe and Asia, has materially extended voyage distances and supported tonne-mile demand. In parallel, strategic stock releases and inventory drawdowns by consuming countries have partially alleviated immediate oil supply shortages, while reinforcing long-haul trading activity and vessel demand. By mid-April, with the Strait of Hormuz still effectively closed, a growing number of ballasting vessels repositioned to the U.S. Gulf, creating a growing risk of oversupply in the Atlantic basin and exerting downward pressure on spot rates as tonnage availability starts to gradually outpace cargo demand. On March 2nd, the TD22 USG (TCE) stood at 154,565 USD/day, spiking at 216,221 USD/day at March 4th, and cooling down gradually over the next weeks to 93,961 USD/day by April 30th. Over the same period, the VLCC utilisation (ratio laden versus ballasters) declined materially, and the number of VLCCs West of Suez increased by 28.8%. This pressure is expected to persist the longer the Strait remains closed, reinforced with broader macroeconomic implications and more pronounced effects on tanker demand.

Once reopened, restocking of global inventories, either to pre-conflict levels or even higher as a buffer against ongoing geopolitical risk, is likely to underpin tanker demand and freight rates. However, over the medium term, the market may revert back to its oversupplied conditions, potentially further accelerated by the United Arab Emirates’ decision to exit OPEC/OPEC+ effective 1 May. In addition, current elevated oil prices and energy dependence are also expected to have a lasting impact on global consumption patterns. Chinese NEV (new energy vehicle) exports continue to set new records, with March year-on-year growth of a staggering 135%. In addition, increased investment in renewable energy as part of broader energy security and independence strategies is expected to accelerate. Chinese solar exports hit 68 GW in March, doubling February volume. South-East Asia leading the jump with march PV imports +200% vs Feb as South-East Asia oil shock fuels search for energy alternatives and independence.

On the supply side, fleet orders increased significantly over the last months. The current OB/F stands at 27.36% for VLCCs, and 28.04% for Suezmaxes – with other databases already reporting OB/F’s 32.6% and 30.6%, respectively. Thereby crude tanker supply surpasses crude tanker tonne-mile trade demand in both 2026 (by -6.8%) and 2027 (by -2.7%). At the same time, fleet aging remains a key consideration. Currently, 43% of VLCCs and 41% of Suezmaxes are older than 15 years, indicating that a significant portion of the fleet will surpass 20 years of age within the next five years.

Euronav has 2 FSOs (average age 24y), 4 (+2NB) VLCCs (average age 1.8y) and 18 Suezmaxes (average age 7.2y) on the water.

Euronav performance highlights (in USD):

 TCE Q1 2026QTD Q2 2026VLCC70,204182,731 (81% fixed)SUEZMAX91,849122,147 (83% fixed)  Delphis – Container Markets4

The conflict in the Middle East has significantly disrupted regional container flows. The Strait of Hormuz is effectively closed to regular container traffic, having previously accounted for around 10% of global boxship capacity calls. Across all container vessel sizes, 129 vessels are currently trapped inside the Persian Gulf, and vessel transits through the strait have dropped sharply to fewer than one per day in March, compared to 20–25 prior to the conflict. Operators are increasingly relying on alternative logistics solutions, including land-based routing via Red Sea ports. Disruption effects are also spreading beyond the immediate region, with congestion hotspots emerging and operational inefficiencies increasing, port capacity utilisation in the Indian Subcontinent has surged to record levels, while average vessel speeds have declined with 2.1%. Expectations for a return to normal Red Sea transits have been pushed further out (again), as liner companies delay rerouting plans amid continued security concerns, including renewed threats in the Gulf of Aden, where containership transits have fallen to an 18-month low.

Hence, container shipping markets unexpectedly strengthened again in March. Time charter rates rose to new post-pandemic highs (and the highest level since September 2022), reflecting increased chartering activity from liner operators seeking to manage operational uncertainty. Freight markets experienced more pronounced impacts, particularly on routes to and from the Middle East Gulf, where disruption has driven higher costs. Elevated bunker prices have also contributed to broader rate increases, with the SCFI spot index rising by 43.3% since end-February to date.

Despite recent strength, market fundamentals suggest a potential softening later in 2026 again. Global seaborne container trade in billion TEU-miles is currently projected to grow by only 1.1% in 2026, down from 4.9% in 2025, and declining further in 2027 by -6.6%. The OB/F ratio stands at 37.7%, and fleet supply is expected to expand by 4.7% in 2026 and 7.6% in 2027. Trade growth forecasts have been revised downward in light of Middle East developments, with regional volumes likely to remain under pressure in the near term. Broader macroeconomic effects, including higher energy costs, are also expected to weigh on global trade flows, though the extent and duration of these impacts remain uncertain.

CMB.TECH’s 4 x 6,000 TEU (average age 1.8y) and 1 NB 1,400 TEU container vessels are all employed under 10 to 15-year time charter contracts.

Bochem – Chemical Markets5

Often overlooked, the Strait of Hormuz is also a critical passage for the global chemical tanker market. Arabian Gulf countries account for approximately 27 million tonnes of chemical exports, and while the strait represents only around 10% of total global chemical exports, its importance is far greater for specific trades. More than 20% of global organic chemical exports transit this route, with methanol, ethylene glycol and styrenics most affected. Asian markets were particularly exposed given their reliance on Middle Eastern supply.

In the immediate aftermath of the disruption, freight rates were supported by vessel dislocation, longer sailing distances and sharply higher war‑risk and insurance costs, despite weakening cargo volumes. As the quarter progressed, reduced Gulf exports translated into outright volume losses, force majeure declarations and lower operating rates at Asian petrochemical plants dependent on Middle Eastern feedstocks. Given the limited availability of alternative supply sources outside the Arabian Gulf, a prolonged closure of the Strait of Hormuz would be expected to result in a sharp decline in global organic chemical trade.

Regional imbalances persisted, with transatlantic and intra‑Asian trades remaining comparatively more resilient than Middle East‑linked routes. By the end of Q1, freight rate resilience increasingly contrasted with deteriorating underlying trade fundamentals, particularly for coated tonnage with higher exposure to organic chemicals.

Looking ahead, chemical tanker demand measured in billion tonne‑miles is forecast to contract by 2.1% in 2026, before recovering by 3.9% in 2027. Fleet supply growth is expected to exceed demand, with the global chemical tanker fleet projected to expand by 8.9% in 2026 and 6.4% in 2027.

Bochem’s 25,000 DWT chemical tankers fleet comprises out of 8 delivered vessels, and 8 NB vessels (average age <1y). They are employed under a 10-year time charter (6 vessels), under a 7-year time charter (6 vessels), and in a spot pool (2 vessels).

Bochem performance highlights (in USD):

 TCE Q1 2026QTD Q2 202625k DWT stainless Steel (Pool)21,45821,063 (33% fixed) Windcat – Offshore Energy Markets6

The CSOV market remained robust in early 2026, with CSOVs benefiting from strong activity over the winter off-season. In Q1, virtually all top-tier CSOVs in Europe found work, a second consecutive winter of near-full utilisation, reflecting healthy demand from both offshore wind and oil & gas projects. Charter rates held firm through the winter stepped up sharply for summer-season contracts, with average spring/summer fixing levels around TCE 58,000–67,000 USD/day and some short-term or oil & gas jobs exceeding TCE of 70,000 USD/day.

For the remainder of 2026, the outlook is positive. Peak summer installation activity is expected to keep CSOVs well employed at solid day rates. However, vessel supply will expand as more than 20 new CSOV deliveries arrive this year, which could introduce excess capacity towards the end of the year (the traditionally quieter winter period) and ease the ultra-tight market conditions seen recently. Nonetheless, rising interest from the oil & gas sector, for example, recent CSOV charters for Brazilian offshore campaigns, provides an additional demand driver, and steady operations & maintenance needs from the growing installed base of wind farms should help support utilisation even if wind project starts slow temporarily. Meanwhile, broader geopolitical factors underline the strategic importance of energy independence: heightened energy security concerns amid current Middle East tensions (including potential disruptions in critical shipping routes) are prompting governments to accelerate both renewable offshore wind projects and oil & gas hydrocarbon investment. These trends, together with disciplined newbuild ordering (no new CSOVs were ordered in Q1 2026), underpin a constructive longer-term demand picture for CSOVs.

The CTV market also saw a solid start to 2026. After a slow January, chartering activity picked up through Q1, by May, the vast majority of European CTVs has been booked for the 2026 maintenance season, with only a handful of vessels left on the spot market. Larger 12- and 24-pax vessels with superior seakeeping and deck capacity were again the preferred choice for most clients. Day rates have remained broadly in line with last year’s levels, with a slight upward trend observed as the season approaches.

Looking ahead, CTV utilisation is expected to stay high through the summer months amid steady offshore service demand. Supply-side dynamics remain favourable: new vessel introductions in 2026 are modest and focused on modern, higher-capacity designs, while ongoing industry consolidation has reduced the risk of overcapacity.

Windcat has 3 (+4NB) CSOVs, and 59(+4NB) CTVs (average age 10.4y).

Windcat performance highlights (in USD):

 TCE Q1 2026QTD Q2 2026CSOV64,83762,301 (100% fixed)CTV2,6093,414 (91% fixed) CONFERENCE CALL
The call will be a webcast with an accompanying slideshow. You can find the details of this conference call below and on the “Investor Relations” page of the website. The presentation, recording & transcript will also be available on this page.

Webcast Information Event Type: Video conference call with slide presentationEvent Date:19 May 2026Event Time:8 a.m. EST / 2 p.m. CETEvent Title: “Q1 2026 Earnings Conference Call”Event Site/URL:  https://events.teams.microsoft.com/event/9600de65-6747-468b-bb10-eb435b6a1780@d0b2b045-83aa-4027-8cf2-ea360b91d5e4 To attend this conference call, please register via the following link.

Telephone participants who are unable to pre-register may dial in to the respective number of their location (to be found here). The Phone conference ID is the following: 266 848 625#

Annual General Meeting – 21 May 2026

About CMB.TECH

CMB.TECH (all capitals) is one of the largest listed, diversified and future-proof maritime groups in the world with a combined fleet of about 250 vessels: dry bulk vessels, crude oil tankers, chemical tankers, container vessels and offshore energy vessels. CMB.TECH also offers hydrogen and ammonia fuel to customers, through own production or third-party producers.

CMB.TECH is headquartered in Antwerp, Belgium, and has offices across Europe, Asia and Africa.

CMB.TECH is listed on Euronext Brussels and the NYSE under the ticker symbol “CMBT” and on Euronext Oslo Børs under the ticker symbol “CMBTO”.

More information can be found at https://cmb.tech

Forward-Looking Statements

Matters discussed in this press release may constitute forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides safe harbour protections for forward-looking statements in order to encourage companies to provide prospective information about their business. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts. The Company desires to take advantage of the safe harbour provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbour legislation. The words "believe", "anticipate", "intends", "estimate", "forecast", "project", "plan", "potential", "may", "should", "expect", "pending" and similar expressions identify forward-looking statements.

The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, our management's examination of historical operating trends, data contained in our records and other data available from third parties. Although we believe that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond our control, we cannot assure you that we will achieve or accomplish these expectations, beliefs or projections.

In addition to these important factors, other important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include the failure of counterparties to fully perform their contracts with us, the strength of world economies and currencies, general market conditions, including fluctuations in charter rates and vessel values, changes in demand for tanker vessel capacity, changes in our operating expenses, including bunker prices, dry-docking and insurance costs, the market for our vessels, availability of financing and refinancing, charter counterparty performance, ability to obtain financing and comply with covenants in such financing arrangements, changes in governmental rules and regulations or actions taken by regulatory authorities, potential liability from pending or future litigation, general domestic and international political conditions, potential disruption of shipping routes due to accidents or political events, vessels breakdowns and instances of off-hires and other factors. Please see our filings with the United States Securities and Exchange Commission for a more complete discussion of these and other risks and uncertainties.

This information is published in accordance with the requirements of the Continuing Obligations on Euronext Oslo Børs.

Contact

CMB.TECH
Katrien Hennin
Head of Marketing and Communications
+32 499 39 34 70
[email protected]

Joris Daman
Head of Investor Relations
Tel: +32 498 61 71 11
[email protected]

Condensed consolidated interim statement of financial position (unaudited)

(in thousands of USD)

          March 31, 2026  December 31, 2025ASSETS             Non-current assets      Vessels          6,441,456  6,323,773Assets under construction          759,807  738,298Right-of-use assets          5,563  4,847Other tangible assets          35,266  23,981Prepayments          —  1,075Intangible assets          13,956  12,710Goodwill          190,689  177,022Receivables          97,794  97,116Investments          132,308  111,346Deferred tax assets          2,705  2,850       Total non-current assets  7,679,544  7,493,018       Current assets      Inventory          82,820  77,175Trade and other receivables          350,513  320,843Current tax assets          3,417  4,912Short-term investments          8,271  —Cash and cash equivalents          194,600  146,529   639,621  549,459       Non-current assets held for sale          137,513  363,097       Total current assets  777,134  912,556       TOTAL ASSETS  8,456,678  8,405,574              EQUITY and LIABILITIES             Equity      Share capital          343,440  343,440Share premium          1,817,557  1,817,557Translation reserve          4,662  9,502Hedging reserve          499  90Treasury shares          (284,508)  (284,508)Retained earnings          1,059,646  737,239       Equity attributable to owners of the Company  2,941,296  2,623,320       Non-current liabilities      Bank loans          2,783,764  2,839,590Other borrowings          1,902,228  1,876,815Lease liabilities          4,565  3,368Other payables          1,983  —Employee benefits          1,177  1,180Provisions          450  —Deferred tax liabilities          27  485       Total non-current liabilities  4,694,194  4,721,438       Current liabilities      Trade and other payables          258,000  222,492Current tax liabilities          9,351  8,288Bank loans          180,717  351,170Other notes          200,327  203,287Other borrowings          171,124  273,898Lease liabilities          1,667  1,681Provisions          2  —       Total current liabilities  821,188  1,060,816       TOTAL EQUITY and LIABILITIES  8,456,678  8,405,574               Condensed consolidated interim statement of profit or loss (unaudited)

(in thousands of USD except per share amounts)

          2026  2025   Jan. 1 - Mar. 31, 2026  Jan. 1 - Mar. 31, 2025Shipping income      Revenue  519,630  235,044Gains on disposal of vessels/other tangible assets  267,354  46,451Other operating income  20,331  7,134Total shipping income  807,315  288,629       Operating expenses      Raw materials and consumables          (1,409)          (2,809)Voyage expenses and commissions          (104,819)  (42,404)Vessel operating expenses          (127,487)  (61,829)Charter hire expenses          (218)  (313)Depreciation tangible assets          (105,860)  (54,854)Amortisation intangible assets          (711)  (817)Impairment reversals          589          —General and administrative expenses  (27,787)  (22,847)Total operating expenses  (367,702)  (185,873)       RESULT FROM OPERATING ACTIVITIES  439,613  102,756       Finance income  12,174  6,237Finance expenses  (93,871)  (70,452)Net finance expenses  (81,697)  (64,215)       Share of profit (loss) of equity accounted investees (net of income tax)          12,096  (51)       PROFIT (LOSS) BEFORE INCOME TAX  370,012  38,490       Income tax benefit (expense)  (1,178)  1,883       PROFIT (LOSS) FOR THE PERIOD  368,834  40,373       Attributable to:      Owners of the company  368,834  43,998Non-controlling interest  —          (3,625)       Basic earnings per share  1.27  0.23Diluted earnings per share  1.27  0.23       Weighted average number of shares (basic)  290,169,769  194,216,835Weighted average number of shares (diluted)  290,169,769  194,216,835                      Condensed consolidated interim statement of comprehensive income (unaudited)

(in thousands of USD)

          2026  2025   Jan. 1 - Mar. 31, 2026  Jan. 1 - Mar. 31, 2025       Profit/(loss) for the period  368,834  40,373       Other comprehensive income (expense), net of tax      Items that will never be reclassified to profit or loss:      Remeasurements of the defined benefit liability (asset)          —          —       Items that are or may be reclassified to profit or loss:      Foreign currency translation differences  (4,840)  4,182Cash flow hedges - effective portion of changes in fair value  409  (1,184)       Other comprehensive income (expense), net of tax  (4,431)  2,998       Total comprehensive income (expense) for the period  364,403  43,371       Attributable to:      Owners of the company  364,403  46,996Non-controlling interest  —  (3,625)               Condensed consolidated interim statement of changes in equity (unaudited)

(In thousands of USD)

 Share capitalShare premiumTranslation reserveHedging reserveTreasury sharesRetained earningsEquity attributable to owners of the CompanyNon-controlling interestTotal equity          Balance at January 1, 2025239,148460,486(2,045)2,145(284,508)777,0981,192,324—1,192,324          Profit (loss) for the period        —        —        —        —        —43,99843,998(3,625)40,373Total other comprehensive income (expense)        —        —4,182(1,184)        —        —2,998—2,998Total comprehensive income (expense)        —        —4,182(1,184)        —43,99846,996(3,625)43,371          Transactions with owners of the company         Business Combination        —        —        —        —        —        41,04141,0411,346,199        1,387,240Total transactions with owners        —        —        —        —        —        41,04141,0411,346,1991,387,240          Balance at March 31, 2025239,148460,4862,137961(284,508)862,1371,280,3611,342,5742,622,935                               Share capitalShare premiumTranslation reserveHedging reserveTreasury sharesRetained earningsEquity attributable to owners of the CompanyNon-controlling interestTotal equity          Balance at January 1, 2026343,4401,817,5579,50290(284,508)737,2392,623,320—2,623,320          Profit (loss) for the period        —        —        —        —        —368,834368,834—368,834Total other comprehensive income (expense)        —        —(4,840)409        ——(4,431)—(4,431)Total comprehensive income (expense)        —        —(4,840)409        —368,834364,403—364,403          Transactions with owners of the company         Dividends to equity holders        ——        —        —        —(46,427)(46,427)—(46,427)Total transactions with owners—————(46,427)(46,427)—(46,427)          Balance at March 31, 2026343,4401,817,5574,662499(284,508)1,059,6462,941,296—2,941,296                      Condensed consolidated interim statement of cash flows (unaudited)

(in thousands of USD)

                 2026  2025   Jan. 1 - Mar. 31, 2026  Jan. 1 - Mar. 31, 2025       Net cash from (used in) operating activities  167,351  33,444       Net cash from (used in) investing activities  204,408  (1,243,591)       Net cash from (used in) financing activities  (324,547)  1,341,620       Net increase (decrease) in cash and cash equivalents  47,212  131,473       Net cash and cash equivalents at the beginning of the period  146,529  38,869Effect of changes in exchange rates  859  (7,457)       Net cash and cash equivalents at the end of the period  194,600  162,886        1 Source: AXS Marine, Clarksons SIN, Breakwave Advisors, BRS, S&P Global, Arctic, Reuters, Rio Tinto, Arrow
2 On 1 January 2026, the Baltic Exchange recalibrated its Capesize index by changing the standard reference vessel from a 180,000 DWT ship to a 182,000 DWT “eco” design. This update increased the baseline Baltic Capesize Index (BCI) time charter average by roughly $3,500 per day
3 Source: AXS Marine, Clarksons SIN, IEA, Commodore Research, Ember
4 Source: Clarksons SIN
5 Source: Clarksons SIN, American Chemical Society, Drewry
6 Source: Clarksons Offshore

CMBT_Q1_2026_Earnings_release_

CMB.TECH NV (CMBT) Q1 2026 Earnings Call Transcript

New integrated workflow combines icIEF fractionation and mass photometry Enables direct characterization of aggregation and size within icIEF-resolved charge variants Four-hour workflow reduces development risk and accelerates biosimilar manufacturing , /PRNewswire/ -- Bio‑Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, and Refeyn, the pioneer in mass photometry technology, today announced a first‑of‑its‑kind integrated workflow for the characterization of charge and size variants in bispecific antibodies and biosimilars.

By combining R&D Systems MauriceFlex™ imaged capillary isoelectric focusing (icIEF) fractionation system with Refeyn's TwoMP mass photometry platform, researchers can directly correlate charge heterogeneity with molecular weight and aggregation at single‑molecule resolution in a streamlined four‑hour workflow.

Bispecific antibodies are among the fastest-growing classes of biotherapeutics, but their structural complexity makes thorough characterization challenging. Incomplete characterization can delay development, increase manufacturing risk, and lead to costly late‑stage failures.

The MauriceFlex™ system delivers high-resolution separation and fractionation of charge variants, a capability increasingly expected in regulatory submissions. However, analyzing the size and aggregation of individual charge fractions has historically been difficult due to the large sample requirements of traditional methods.

The integrated workflow addresses this challenge directly by pairing icIEF fractionation with mass photometry. Charge variants are first separated using MauriceFlex™, then analyzed on Refeyn's TwoMP platform, which requires only nanogram‑level sample and reveals size distribution and aggregation at single‑molecule resolution.

Together, the technologies enable direct characterization of aggregation and size within icIEF-resolved charge variants—an insight not accessible with standalone methods—reducing reliance on multiple tests and enabling faster, more efficient process development.

"Bispecifics are the fastest growing segment within next‑generation antibodies, but they are very difficult to characterize. This approach directly addresses one of the biggest challenges by combining icIEF fractionation with mass photometry. Researchers can now interrogate charge and size variants together in a single workflow," said Gerry Mackay, CEO of Refeyn.

"Our customers are under intense pressure to develop and manufacture increasingly complex biologics faster and more efficiently. Enabling deeper characterization with less sample helps them reduce risk, control costs, and make better decisions earlier in development," said Will Geist, President Bio‑Techne Protein Sciences Segment.

In a joint webinar, scientists demonstrated the workflow using Mosunetuzumab‑axgb and a biosimilar, tracking size-related changes in the molecule across charge variant fractions under multiple conditions. An application note with full findings is available here.

The workflow will also be presented at the American Society for Mass Spectrometry (ASMS) conference, taking place May 31 – June 4, 2026, in San Diego. See booth and poster details here

ABOUT BIO‑TECHNE

Bio‑Techne Corporation (NASDAQ: TECH) is a global life sciences company headquartered in Minnesota, celebrating 50 years of empowering scientific and diagnostic communities to reach better answers. The company provides high‑quality reagents, analytical instruments, and precision diagnostics. Its portfolio is organized into three customer‑focused brands: R&D Systems™, Bio‑Techne Spatial™, and Bio‑Techne Diagnostics™, reflecting the scientific journey from discovery to translational research to clinical decision making. Bio‑Techne operates in 34 locations worldwide and employs approximately 3,000 people. In fiscal year 2025, the company generated over $1.2 billion in net sales. Its more than 500,000 products are used globally by academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories.

For more information on Bio‑Techne, please visit www.bio-techne.com or follow the company on LinkedIn, X, or YouTube.

ABOUT REFEYN

Refeyn specializes in the development, production, and distribution of mass photometry solutions for industry and academia. Its innovative technology enables accurate mass measurement of single molecules in their native state without labels, delivering faster insights with minimal sample compared to conventional methods.

For more information on Refeyn, please visit www.refeyn.com or follow the company on LinkedIn or YouTube.

MEDIA CONTACTS:

Bio‑Techne
David Clair, Vice President Investor Relations
[email protected] 

Corporate Communications
[email protected] 

Refeyn
Catie Lichten
Scientific Communications Manager
[email protected] 

SOURCE Bio-Techne Corporation